ArticleFrontiers in genome editing2026
CRISPR-SWITCH (silent mutations with intention to create heterozygotes): a strategy for monoallelic genome editing and generation of a
Article in Frontiers in genome editing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precise control of allelic outcomes remains a major limitation of CRISPR-Cas9 genome editing, particularly for genes in which biallelic modification is lethal or confounds disease modeling. Here, we present CRISPR-SWITCH (Silent mutations With Intention To Create Heterozygotes), a genome engineering strategy that enables deliberate monoallelic editing by exploiting allele-specific CRISPR targeting. CRISPR-SWITCH operates through the initial introduction of a synonymous nucleotide substitution that creates a unique guide RNA recognition site, allowing subsequent selective editing of the engineered allele while preserving the wildtype copy. We applied CRISPR-SWITCH to generate a mouse model of Baker-Gordon syndrome, a dominant-negative neurodevelopmental disorder caused by pathogenic variants in synaptotagmin-1 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.